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Background: In oncology, health-related quality of life (HRQoL) data are often collected using disease-specific
patient questionnaires while generic, patient-level utility data required for health economic modeling are often not
collected.
Methods: We developed a mapping algorithm for multiple myeloma that relates HRQoL scores from the European
Organization for Research and Treatment of Cancer (EORTC) questionnaires QLQ-C30 and QLQ-MY20 to a utility
value from the European QoL-5 Dimensions (EQ-5D) questionnaire. Data were obtained from 154 multiple myeloma
patients who had participated in a multicenter cohort study in the UK or Germany. All three questionnaires were
administered at a single time point. Scores from all 19 domains of the QLQ-C30 and QLQ-MY20 instruments were
univariately tested against EQ-5D values and retained in a multivariate regression model if statistically significant. A
10-fold cross-validation model selection method was also used as an alternative testing means. Two models were
developed: one based on QLQ-C30 plus QLQ-MY20 scores and one based on QLQ-C30 scores alone. Adjusted
R-squared, correlation coefficients, and plots of observed versus predicted EQ-5D values were presented for both
models.
Results: Mapping revealed that Global Health Status/QoL, Physical Functioning, Pain, and Insomnia were significant
predictors of EQ-5D utility values. Similar results were observed when QLQ-MY20 scores were excluded from the
model, except that Emotional Functioning and became a significant predictor and Insomnia was no longer a
significant predictor. Adjusted R-squared values were of similar magnitude with or without inclusion of QLQ-MY20
scores (0.70 and 0.69, respectively), suggesting that the EORTC QLQ-MY20 adds little in terms of predicting utility
values in multiple myeloma.
Conclusions: This algorithm successfully mapped EORTC HRQoL data onto EQ-5D utility in patients with multiple
myeloma. Current mapping will aid in the analysis of cost-effectiveness of novel therapies for this indication.
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Utility valuesBackground
Economic evaluations are an increasingly important aspect
of drug development. The cost-utility analysis of a novel
therapy is typically assessed in terms of cost per quality-
adjusted life-year (QALY) gained, where QALYs reflect
both survival and health-related quality of life (HRQoL)
[1,2]. Health-state utility values, which represent an* Correspondence: Irina.Proskorovsky@evidera.com
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captured by patient questionnaires, are commonly used
by researchers to calculate QALYs. These values are
generated by applying an appropriate utility algorithm
to the patients’ responses to the questionnaires, and are
depicted as an interval scale in which 1 represents per-
fect health and 0 reflects a health state equivalent to
death [1,2]. The most common type of questionnaire
used to calculate health-state utility is the EuroQol-5
Dimensions (EQ-5D), a simple questionnaire that takes
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state utility values, preference-based instruments such
as the EQ-5D allow health service providers with a means
to compare QALYs across different patient groups and
disease types, which can aid in decisions regarding broader
healthcare resource allocation [1,2].
The measurement of HRQoL in the oncology setting
is usually carried out using cancer-specific instruments
rather than generic preference-based measures as they
focus on relevant health problems, and tend to capture
more clinically meaningful differences [4,5]. The use of
core questionnaires, such as the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 (EORTC QLQ-C30) [6] is standard
practice, with these often supplemented with condition-
associated modules. Preference-based measures of health
status, however, are rarely used. Two recent trials evaluat-
ing novel therapies for patients with multiple myeloma,
for example, assessed HRQoL using EORTC QLQ-C30
with or without its myeloma-specific module EORTC
QLQ-MY20, yet neither trial collected EQ-5D data [6,7].
From an economic perspective, preference-based instru-
ments are required as they can be readily applied at the
population level for economic analysis. In the absence of
data from preference-based instruments, researchers may
utilize suboptimal, non-specific measures, such as clinical
response levels, to derive utility values [8].
Mapping algorithms is an alternative means of relating
HRQoL scores from core and disease-specific modules
to generic utility values. Several studies have demon-
strated the feasibility of mapping EORTC HRQoL data
to EQ-5D values in cancer patients [4,9-13], including
those with breast cancer [10,12], prostate cancer [13],
esophageal cancer [4], and gastric cancer [11]. However
data on the ability to map EORTC HRQoL data to EQ-5D
in patients with multiple myeloma are limited [14,15]. The
goal of the current study was to develop a mapping algo-
rithm that uses HRQoL data from the EORTC QLQ-C30
(with or without QLQ-MY20 data) to estimate EQ-5D
utility values in patients with multiple myeloma, to facili-




HRQoL data from a bi-national, multicenter, cohort study
in patients with multiple myeloma were used for this ana-
lysis [16]. In addition to information collected from med-
ical charts, supplementary data were collected at the first
treatment visit after study enrolment, both from patient
interviews and from 3 self-administered HRQoL question-
naires: EOTRC QLQ-C30, EORTC QLQ-MY20, and
EQ-5D. Eligible patients, who were aged ≥ 18 years and
had a current diagnosis of multiple myeloma, werecategorized into one of four pre-defined subgroups at the
time of the study visit: asymptomatic, mildly symptomatic,
moderately symptomatic, or severely symptomatic. Pa-
tients were ineligible if they had undergone autologous
stem cell transplantation (ASCT) within the past 3 months
or had received experimental treatment from a clinical
trial. The study was approved by the institutional review
boards of the participating centres and conducted accord-
ing to the Declaration of Helsinki International Confer-
ence on Harmonization and the guidelines for Good
Clinical Practice. Written informed consent was obtained
from all patients before enrolment.
Instruments
EORTC QLQ-C30
The EORTC QLQ-C30 is a validated 30-item question-
naire containing both single- and multi-item measures
[7,17], Additional file 1. These include five functional
scales (Physical, Role, Cognitive, Emotional, and Social
Functioning), three symptom scales (Fatigue, Pain, and
Nausea/Vomiting), a Global Health Status/QoL scale,
and six single items (Constipation, Diarrhea, Insomnia,
Dyspnea, Appetite Loss, and Financial Difficulties). Scores
for each scale and single-item measure are averaged and
transformed linearly to a score ranging from 0–100. A
high score for functional scales and for Global Health
Status/QoL represent better functioning ability or HRQoL,
whereas a high score for symptom scales and single items
represents significant symptomatology.
EORTC QLQ-MY20
The EORTC QLQ-MY20 is a validated instrument, rec-
ommended as a supplement to the QLQ-C30 instrument
in patients with multiple myeloma [7,18], Additional file 2.
The module comprises 20 questions that address four
myeloma-specific HRQoL domains: Disease Symptoms,
Side Effects of Treatment, Future Perspective, and Body
Image. Three of the four QLQ-MY20 domains are multi-
item scales: Disease Symptoms (includes bone aches or
pain, back pain, hip pain, arm or shoulder pain, chest pain,
and pain increasing with activity); Side Effects of Treat-
ment (includes drowsiness, thirst, feeling ill, dry mouth,
hair loss, upset by hair loss, tingling hands or feet, restless-
ness/agitation, acid indigestion/heartburn, and burning or
sore eyes); and Future Perspective (includes worry about
death and health in the future, and thinking about illness).
The Body Image scale is a single-item scale that ad-
dresses physical attractiveness. As with the QLQ-C30,
QLQ-MY20 domain scores are averaged and transformed
linearly to a score ranging from 0–100. A high score for
Disease Symptoms and Side Effects of Treatment repre-
sents a high level of symptomatology or problems,
whereas a high score for Future Perspective and Body
Image represents better outcomes.
Table 1 Baseline patient and disease characteristics
Variable Overall (N = 154)
Male – n (%) 97 (63%)
Age – Mean (SD) 66.4 (10.0)






Mildly symptomatic 48 (31%)
Moderately symptomatic 50 (33%)
Severely symptomatic 39 (25%)
Number of co-morbidities present





Duration of MM (yrs) – Mean (SD) 3.7 (3.7)
Previous ASCT 18 (12%)
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The EQ-5D is a self-administered questionnaire (Additional
file 3) consisting of five dimensions (Mobility, Self-Care,
Pain, Usual Activities, and Anxiety/Depression), and a
health status rating scale. Each dimension has three levels
of “severity” corresponding to the degree of problems en-
countered: ‘none’, ‘some’, and ‘extreme’. The instrument
provides a simple descriptive profile for each participant.
Information relating to EQ-5D health states gathered in
the context of multinational trials can be converted into a
single summary index using one of the available EQ-5D
value sets [3]. For this study, UK value sets were used to
calculate health utility for all patients. The health utility
score can range from −0.594 to 1.0, with 1.0 representing
perfect health. The instrument also allows the subject to
evaluate his/her current health state on a visual analogue
scale that ranges from 0 (worst imaginable health state) to
100 (best imaginable health state).
Analysis
Multiple linear regression analysis was used to derive a
mapping algorithm from EORTC QLQ-C30 and QLQ-
MY20 to EQ-5D values. Each scale/item was tested in
univariate models against utility. The first multivariate
model was then fitted by including scales/items that
were found to have a statistically significant association
with utility in univariate analysis (p < 0.1). The first
multivariate model was then manually trimmed down by
sequentially removing non-significant predictors with
the highest p-value until the final model included only
significant predictors (p < 0.1). Goodness-of-fit of the full
model (including all scales of QLQ-C30 and QLQ-MY20)
and the model including significant predictors only, was
compared using adjusted R-squared values. The predictive
ability of the final model was assessed by root mean
square error (RMSE) and by comparing predicted and ob-
served EQ-5D utility values. External validation was not
possible given the lack of comparable datasets in multiple
myeloma in which all three questionnaires were admin-
istered. Therefore, as an alternative, a 10-fold cross-
validation model selection method was used to assess
predictive ability of the mapping. In 10-fold cross-
validation, the data are split into 10 approximately
equivalent sized parts. The model is fitted on 9 data
parts with the 10th being held out for validation. Specif-
ically, the fitted model of the 9 selected parts is used to
compute the predicted residual sum of squares on the
10th omitted part, and this process is repeated for each
of the 10 parts. The sum of the 10 predicted residual
sums of squares is obtained for each fitted model and is
the estimate of the prediction error that is denoted by
CVPRESS. Among all possible models with varying
numbers and combinations of HRQoL scales, the model
with the smallest CVPRESS statistic is then selected.The K-fold cross-validation method is commonly used
when the aim of the regression model is prediction [19].
Among all candidate models, the model with the smal-
lest CVPRESS statistic has the best predictive ability. In
addition, observed vs. predicted EQ-5D values were ex-
amined overall and by symptom severity group. This
model-building process was repeated to develop a map-
ping equation based on the QLQ-C30 instrument alone,
for application in studies that did not apply the QLQ-
MY20 instrument.
Results
Patient characteristics, HRQoL scores, and utility values
The study enrolled 154 patients (89 in the UK and 65 in
Germany). Baseline patient characteristics are listed in
Table 1. Approximately two-thirds of the patients were
male, and the average (± standard deviation [SD]) age at
enrolment was 66 ± 10 years. Most patients (83%) were of
British or German descent. The average time from diagno-
sis was 3.7 ± 3.7 years, and most patients (88%) had never
undergone autologous stem cell transplant (ASCT).
The distribution of EQ-5D, EORTC QLQ-C30, and
EORTC QLQ-MY20 scores are summarized in Table 2.
The average utility value was 0.7 ± 0.3 and the interquartile
range (IQR) was 0.62 to 1.00. The minimum observed util-
ity value was −0.13 and the maximum was 1.0. The mean
QLQ-C30 Global Health Status/QoL score was 60.1 ± 25.5
and the IQR was 41.7 to 83.3. Mean Cognitive and Emo-
tional Functioning scores were near or above 80, and these
Table 2 Distribution of EQ-5D, EORTC QLQ-C30 and EORTC QLQ-MY20 scores
No. of patients Mean ± SD Median Interquartile range
EQ-5D 154 0.7 ± 0.3 0.73 0.62–1.00
EORTC QLQ-C30
Global health status/QoL 154 60.1 ± 25.5 58.3 41.7–83.3
Functional scales
Physical 154 68.7 ± 27.2 73.3 53.3–93.3
Role 153 62.9 ± 34.6 66.7 33.3–100.0
Emotional 154 78.1 ± 24.6 83.3 66.7–100.0
Cognitive 154 81.4 ± 22.9 83.3 66.7–100.0
Social 154 63.9 ± 32.9 66.7 33.3–100.0
Symptom scales
Fatigue 154 38.6 ± 29.8 33.3 11.1–66.7
Nausea/Vomiting 154 5.2 ± 11.8 0.0 0.0–0.0
Pain 154 32.3 ± 33.4 16.7 0.0–66.7
Single items
Dyspnea 154 21.9 ± 30.6 0.0 0.0–33.3
Insomnia 154 25.1 ± 29.8 16.7 0.0–33.3
Appetite Loss 154 15.4 ± 27.0 0.0 0.0–33.3
Constipation 154 17.7 ± 28.6 0.0 0.0–33.3
Diarrhea 154 8.4 ± 21.7 0.0 0.0–0.0
Financial difficulties 154 18.4 ± 31.2 0.0 0.0–33.3
EORTC QLQ-MY20
Disease symptoms 154 23.3 ± 22.3 16.7 0.0–38.9
Side-effects of treatment 154 19.5 ± 17.1 14.8 7.4–29.6
Future perspective 154 59.9 ± 28.1 66.7 33.3–77.8
Body image 154 77.9 ± 30.5 100.0 66.7–100.0
SD standard deviation.
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100]), Social (63.9 [IQR 33.3 to 100]), and Physical Func-
tioning (68.7 [IQR 53.3 to 93.3]). Mean Pain and Fatigue
scores were 32.3 and 38.6, respectively, and mean Insom-
nia and Dyspnea scores were 25.1 and 21.9, respectively.
Diarrhea and Nausea/Vomiting scales had the lowest
mean scores (< 10). For the QLQ-MY20 instrument, Body
Image scores were generally high (77.9 [IQR 66.7 to 100]),
but Future Perspective scores appeared to be relatively
more affected (59.9 [IQR 33.3 to 77.8]). The Disease
Symptom (23.3 [IQR 0 to 38.9]) and Side Effect scale
scores (19.5 [IQR 7.4 to 29.6]) were roughly consistent in
numbers with the symptom scales from the QLQ-C30.
Mapping QLQ-C30 and QLQ-MY20 to EQ-5D
Results from multiple regression analysis are summarized
in Table 3. Full model results, which included all scales
and individual items from both EORTC QLQ-C30 and
EORTC QLQ-MY20, had an adjusted R-squared value of
0.7015. A trimmed model that included only significant
predictors had an adjusted R-squared value of 0.7028,suggesting that the trimmed model fits the data as well as
the full model, and both models explain a large part of the
observed variation in EQ-5D scores. The final trimmed
model included Global Health Status/QoL, Physical Func-
tioning, Pain, Insomnia and Future Perspective. Better
Global Health Status/QoL and Physical Functioning and
Future Perspective were associated with higher utility
values, as was Insomnia. Pain had a significant negative as-
sociation with utility values. The full and trimmed models
had very similar predictive ability with RMSE indices of
0.164 and 0.163, respectively. The trimmed model also
had the lowest CVPRESS statistic as generated during the
validation phase, thus highlighting its best predictive per-
formance amongst all candidate models tested. A plot of
observed versus predicted utility scores from the trimmed
model indicates that the model fits the data well (Pearsons
correlation coefficient = 0.84; Figure 1). Differences be-
tween observed and predicted mean EQ-5D utility values
by symptom subgroup from the QLQ-C30 +MY20 model
are also presented in Table 4. The mean difference was
smallest for the moderately symptomatic patients (−0.004)
Table 3 Multiple regression analyses mapping EORTC QLQ-C30 and EORTC QLQ-MY20 data to EQ-5D
Predictors Full model Trimmed model
Estimate p-value Estimate p-value
QLQ-C30
Intercept 0.11979 0.3757 0.25763 0.0002
Global health status/QoL* 0.00161 0.0568 0.00165 0.0301
Physical functioning* 0.00471 < 0.0001 0.00467 < 0.0001
Role functioning 0.00073194 0.3455 NS NS
Emotional functioning 0.00104 0.2522 NS NS
Cognitive functioning −0.00037864 0.6203 NS NS
Social functioning 0.00044712 0.4983 NS NS
Fatigue −0.00005750 0.9521 NS NS
Nausea/Vomiting 0.00053330 0.7166 NS NS
Pain* −0.00229 0.0039 −0.00293 < 0.0001
Dyspnoea 0.00037610 0.5099 NS NS
Insomnia* 0.00096618 0.0570 0.00089197 0.0616
Appetite loss −0.00047987 0.4899 NS NS
Constipation −0.00055193 0.3057 NS NS
Financial difficulties 0.00096199 0.0613 NS NS
QLQ-MY20
Disease symptoms −0.00094431 0.3983 NS NS
Side effects 0.00207 0.1445 NS NS
Future perspective* 0.00149 0.0366 0.00157 0.0061
Body image −0.00040870 0.4607 NS NS
Adjusted R-squared values 0.7015 0.7028
RMSE indices 0.164 0.163
*Significant predictors in the full model.
NS not significant.
Figure 1 Observed and predicted EQ-5D utility from trimmed model with EORTC QLQ-C30 and QLQ-MY20.
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Table 4 Observed vs. Predicted EQ-5D Utility by symptom
group from QLQ-C30 +MY20 model
Actual Predicted (95% CI) Difference
Symptom group
Asymptomatic 0.923 0.893 (0.819; 0.967) 0.030
Mildly symptomatic 0.806 0.833 (0.783; 0.883) −0.027
Moderately symptomatic 0.675 0.679 (0.616; 0.743) −0.004
Severely symptomatic 0.501 0.474 (0.398; 0.551) 0.027
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deviate by more than 0.030 from the observed values. Ob-
served utility values for all symptom groups were within
95% CI of the predicted mean utility.
Mapping QLQ-C30 to EQ-5D
Results from multiple regression analysis using EORTC
QLQ-C30 data only, are summarized in Table 5. The
final trimmed model included Global Health Status/
QoL, Physical Functioning, Emotional Functioning, and
Pain (Table 5). Better Global Health Status/QoL, Physical
Functioning, and Emotional Functioning were associated
with higher utility values, whereas a higher Pain score (i.e.,
worse pain) was associated with lower utility values. Both
models had similar and good explanatory power (adjusted
R-squared values of 0.6956 for the full model and 0.6941
for the trimmed model). Predictive ability of both modelsTable 5 Multiple regression analyses mapping QLQ-C30
data to EQ-5D
Predictors Full model Trimmed model
Estimate p-value Estimate p-value
Intercept 0.15540 0.2192 0.23004 0.0042
Global health status/QoL* 0.00198 0.0180 0.00191 0.0106
Physical functioning* 0.00463 < 0.0001 0.00478 < 0.0001
Role functioning 0.00058079 0.4512 NS NS
Emotional functioning* 0.00141 0.0696 0.00136 0.0405
Cognitive functioning −0.00048664 0.5075 NS NS
Social functioning 0.00059878 0.3536 NS NS
Fatigue 0.00016137 0.8588 NS NS
Nausea/Vomiting 0.00041262 0.7764 NS NS
Pain* −0.00249 0.0001 −0.00249 < 0.0001
Dyspnea 0.00060165 0.2879 NS NS
Insomnia 0.00082466 0.1039 NS NS
Appetite loss −0.00037029 0.5885 NS NS
Constipation −0.00050445 0.3468 NS NS
Financial difficulties 0.00079559 0.1187 NS NS
Adjusted R-squared values 0.6956 0.6941
RMSE indices 0.165 0.165
*Significant predictors in the full model.
NS not significant.was also comparable (RMSE of 0.165 for both the full and
trimmed models). Again, the trimmed model had the low-
est CVPRESS, suggesting it has optimal generalizability
compared with all other iterations tested during the valid-
ation phase. A plot of observed versus predicted utility
scores from the trimmed model indicates that the model
fits the data well (Pearsons correlation coefficient = 0.84;
Figure 2). Differences between observed and predicted
mean EQ-5D utility values by symptom subgroup from
the QLQ-C30 model only, are presented in Table 6. The
mean difference was smallest for the moderately symp-
tomatic subgroup of patients (−0.007) and, for all sub-
groups, predicted values did not deviate by more than
0.031 from observed values. Observed utility values for all
symptom severity groups were all within 95% CI of pre-
dicted mean utility.
Discussion
This study reports the mapping of EORTC QLQ-C30
scores (with and without QLQ-MY20 scores) to EQ-5D
utility values in patients with multiple myeloma. The
ability to estimate utility values based on HRQoL data is
beneficial in this setting since recent major trials of
novel agents in multiple myeloma have not collected
preference-based data [6,7]. Although the information
on physical and mental health provided by EORTC
QLQ-C30 and QLQ-MY20 questionnaires offer great
insight to clinicians, the questionnaires are not pertinent
to cost-utility analyses as they are not easily translated
into global health-utility values.
Mapping algorithms is an alternative means of relating
HRQoL scores from core and disease-specific modules
to generic utility values, and similar mappings have been
developed in other cancer populations. In a study of 48
patients with gastric cancer, Kontodimopoulos and col-
leagues [11] demonstrated the ability of QLQ-C30 scores
to predict 15D, Short Form-6D (SF-6D) and, to a lesser
extent, EQ-5D utility values. McKenzie and Van der Pol
[4] mapped QLQ-C30 scores to EQ-5D in 199 patients
with inoperable esophageal cancer in a similar type of
study using regression analysis techniques. In both studies,
however, the model fit was somewhat lower (adjusted
R-square 0.61 for both) compared with current mapping
(adjusted R-square of 0.69). In a study of 280 patients
with hormone-refractory prostate cancer, Wu and col-
leagues [13] developed models to predict EQ-5D utility
values based on QLQ-C30, Functional Assessment of
Cancer Therapy-Prostate (FACT-P) scores, and patient
demographics using ordinary least square regression
analysis. However, this mapping can only be used when
both QLQ-C30 and FACT-P scores are collected within
the same study.
Two previous studies have reported mapping algorithms
involving multiple myeloma. Rowen and colleagues [14]
Figure 2 Observed and predicted EQ-5D utility from trimmed model with EORTC QLQ-C30 only.
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with multiple myeloma, but used a custom-designed
preference-based measure (EORTC-8D), rather than the
more generic EQ-5D. Versteegh and colleagues [15]
mapped QLQ-C30 scores to EQ-5D using a dataset de-
rived from a HOVON trial of patients with previously
untreated multiple myeloma (HOVON 24); the predict-
ive value of this model was validated in a population of
patients with non-Hodgkin lymphoma (HOVON 25). In
this model, including only significant predictors, all
other domains of QLQ-C30 were the same as in our
study, however the model fit was not as good (R-square
0.51). Neither of the two mapping studies in multiple
myeloma addressed the contribution of EORTC QLQ-
MY20 scores.
The HRQoL scales identified in this analysis as signifi-
cant predictors of utility values, such as Global Health
Status/QoL, Physical Functioning, and Pain, are similar
to HRQoL scales that have been pre-selected as clinically
relevant in previous assessments [7,20]. Our final model
included Global Health Status/QoL, Physical Functioning,
Pain, Insomnia, and Future Perspective when both QLQ-
C30 and QLQ-MY20 were used. Using QLQ-C30 alone,Table 6 Observed vs. Predicted EQ-5D Utility by Symptom
Group from QLQ-C30 Model
Actual Predicted (95% CI) Difference
Symptom group
Asymptomatic 0.923 0.892 (0.816; 0.968) 0.031
Mildly symptomatic 0.806 0.830 (0.780; 0.880) −0.024
Moderately symptomatic 0.675 0.682 (0.617; 0.747) −0.007
Severely symptomatic 0.501 0.476 (0.404; 0.548) 0.025the final model also included Emotional Functioning
alongside Global Health Status/QoL, Physical Functioning,
and Pain. The adjusted R-squared value for both models
was around 0.70, signifying a strong association and
predictability. The high R-squared values and correl-
ation between observed and predicted utility values of
0.84, suggest that the algorithm performs very well. A
limitation to the above findings is the reverse associ-
ation found between Insomnia and EQ-5D (i.e. worse
insomnia associated with higher utility) when testing
HRQoL domains from both the QLQ-C30 and QLQ-
MY20 instruments. Unlike all other statistical associa-
tions, this is a counterintuitive finding. Insomnia was
no longer a significant predictor when only QLQ-C30
domains were used as predictors for EQ-5D. Beside the
almost equal predictability of HRQoL domains from the
QLQ-C30 alone as compared to testing of HRQoL do-
mains from both the QLQ-C30 and the QLQ-MY20, this
provides an additional argument for using the QLQ-C30
as a stand-alone instrument for mapping onto EQ-5D.
Table 2 also indicates possible floor effects on disease-
specific symptom scores Dyspnea, Constipation, Appetite
Loss, Diarrhea, and Nausea/Vomiting, all with median
scores of 0.0, suggesting that these symptoms were not
perceived at all by more than half of all patients. The five
above-mentioned disease-specific symptoms are known to
be reported in the context of novel treatments, and it is
therefore possible that these scores in particular have been
underreported in the context of this study. However, since
our model displays comparably strong predictive power,
independent of the symptom group chosen (see Tables 4
and 6), this does not reduce the predictability of the map-
ping algorithm presented here. Finally, further validation
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here using external containing all three instruments is
recommended.Conclusion
The derived mapping algorithm establishes a link between
EORTC HRQoL data and the EQ-5D as a utility-based
outcomes measure specifically in patients with multiple
myeloma. The results of the study are very encouraging in
terms of the predicting power of mappings from QLQ-
C30 scores alone or in combination with QLQ-MY20.
This mapping algorithm will be a beneficial tool for deriv-
ing utility values from data obtained using the QLQ-C30
with or without the myeloma-specific instrument, and will
thus enable to conduct cost-utility analyses. From a clin-
ical perspective, the results may provide good guidance
with regards to HRQoL domain selection for the purpose
of primary analysis. Given the quantity of HRQoL data
typically generated, a detailed discussion on all available
HRQoL domains is often difficult to accomplish in the
context of peer-reviewed publications. The results pre-
sented here provide an indication of the HRQoL domains
that may be of particular interest in best describing a mye-
loma patient’s general health state and quality of life.Additional files
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